Biosimilars Approval to Biogenerics in Clinical Practice


 



Biological medicines are much more structurally complex and extremely sensitive to manufacturing conditions and therefore more difficult to characterize and produce than small molecule drugs. Even minor changes in manufacturing may lead to significant variations of the cellular systems used for biological production, as well as to differences in the structure, stability, or other quality aspects of the end product, all of which have the potential to affect tolerability and/or efficacy and increase the risk of immune responses. Owing to these issues, specific regulatory guidance on Biosimilars is continuously evolving, and there is some disagreement on which studies need to be implemented to approve a Biosimilars. According to current literature, the following points on Biosimilars deserve consideration: Biosimilars development is characterized by global harmonization, although several not fully answered questions remain regarding extrapolation of indications, switching or interchange ability, and tolerability; in patients with rheumatic diseases, the tolerability and efficacy of Biosimilars in clinical practice remain to be established; several medical and patient associations have published position papers on Biosimilars requesting that safety, efficacy, and traceability be carefully considered; long-term post marketing studies should be implemented to allow physicians to gain confidence in Biosimilars.



 


    Related Conference of Biosimilars Approval to Biogenerics in Clinical Practice

    February 14-15, 2023

    8th Pharmaceutical Chemistry Conference

    Paris, France
    February 20-21, 2023

    20th Annual Meet on Pharmaceutical Sciences

    Rome, Italy
    March 10-11, 2023

    Global Pharmaceutical and Pharma Industry Conference

    Brussels, Belgium
    March 13-14, 2023

    33rd Annual European Pharma Congress

    Frankfurt, Germany
    March 27-28, 2023

    16th Global Pharmacovigilance & Clinical Trials Summit

    Vancouver, Canada
    April 03-04, 2023

    16th European Biosimilars Congress

    Barcelona, Spain
    April 25-26, 2023

    4th Annual Congress on Antibiotics and Bacterial Infections

    Amsterdam, Netherlands
    May 07-08, 2023

    Advanced-Materials 2023

    Valencia, Spain
    July 25-26, 2023

    36th World Congress on Pharmacology

    Amsterdam, Netherlands
    August 11-12, 2023

    38th World Congress on Pharmacology and Therapeutics

    Singapore City, Singapore
    August 28-29, 2023

    23rd International Pharmaceutical Conference and Expo

    Vancouver, Canada
    September 06-07, 2023

    16th World Drug Delivery Summit

    London, UK
    September 14-15, 2023

    10th international conference on Physiotherapy

    Bangkok, Thailand
    September 27-28, 2023

    3rd World Congress on Rare Diseases & Orphan Drugs

    Amsterdam, Netherlands
    September 27-28, 2023

    8th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    October 09-10, 2023

    20th International Conference on Pharmaceutical Chemistry

    Barcelona, Spain
    October 12-13, 2023

    26th World Congress on Nursing, Pharmacology and Healthcare

    Budapest, Hungary
    November 09-10, 2023

    11th International Conference on Clinical Trials

    London, UK
    November 10-11, 2023

    3rd World Biosimilars & Biologics Congress

    Berlin, Germany
    December 05-06, 2023

    2nd World Congress on Precision and Personalized Medicine

    Zurich, Switzerland

    Biosimilars Approval to Biogenerics in Clinical Practice Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in